News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

November 8, 2017 Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
August 24, 2017 Apellis Pharmaceuticals Announces that APL-2 Met its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
August 10, 2017 Apellis Pharmaceuticals Announces $60 Million Series E Financing
June 29, 2017 Apellis Pharmaceuticals Announces Positive Data from APL-2 Studies Showing Rapid and Durable Improvements in LDH and Hemoglobin Levels in PNH
March 24, 2017 Apellis Pharmaceuticals Announces Formation of Scientific Advisory Board
March 9, 2017 Apellis Receives EMA Orphan Drug Designation for APL-2 in PNH
February 14, 2017 Apellis Pharmaceuticals Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program
August 8, 2016 Apellis Pharmaceuticals Announces Appointment of Dr. Robert Kim as Chief Medical Officer
June 23, 2016 Apellis Announces Positive Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor
July 15, 2015 Apellis Pharmaceuticals Announces Formation of Scientific Advisory Board